NEW YORK (GenomeWeb News) – Molecular diagnostics firm IMDx reported on Thursday that it has entered into an agreement with Abbott to design, develop, and manufacture assays using Abbott's FDA-approved m2000 platform.
Privately held IMDx will also bring the assays through the regulatory process.
Financial and other terms of the multi-year deal were not disclosed.
The tests covered by the agreement include assays for Clostridium difficile, vancomycin-resistant Enterococci; Group B Streptococci; Influenza A/Influenza B, and Herpes simplex virus types 1 and 2. Two other tests, for determining the viral load for Epstein-Barr virus and for BK virus, will be commercialized outside the US, Cambridge, Mass.-based IMDx said.
The company uses its proprietary bioinformatics process to create its tests, ensuring products that are optimized and in silico verified, it said.